RadNet (RDNT) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change. A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years. Since a changing ea ...

LOS ANGELES, June 03, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Dr. Howard Berger, President and Chief Executive Officer, will be presenting at the Jefferies 2024 Global Healthcare Conference on Wednesday, June 5, 2024 at 11:30 a.m. Eastern Time. There will be simultaneous and archived webcasts available at https:// ...

There will be simultaneous and archived webcasts available at https://wsw.com/webcast/jeff302/rdnt/1856896 and www.radnet.com under the "About RadNet'' menu section and "News and Press Releases'' sub-menu of the website. LOS ANGELES, June 03, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Dr. Howard Berger, President and ...

Exhibit 99.1 FOR IMMEDIATE RELEASE RadNet Reports First Quarter Financial Results with Record First Quarter Revenue, Adjusted EBITDA and Adjusted Earnings and Revises Upwards 2024 Financial Guidance Ranges LOS ANGELES, California, May 8, 2024 – RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost- effective, fixed-site outpatient diagnostic imaging services through a network of 375 owned and operated outpatient imaging centers, today reported financial results for its first quarter ...

[PART I – FINANCIAL INFORMATION](index=4&type=section&id=PART%20I%20%E2%80%93%20FINANCIAL%20INFORMATION) [Financial Statements](index=4&type=section&id=ITEM%201.%20Financial%20Statements) This section presents RadNet, Inc.'s unaudited condensed consolidated financial statements for Q1 2024 and 2023, including balance sheets, statements of operations, comprehensive income, stockholders' equity, and cash flows, along with explanatory notes Condensed Consolidated Financial Highlights (Q1 2024 vs Q1 2023) | Financial Metric | Q1 2024 (in thousands) | Q1 2023 (in thousands) | | :--- | :--- | :--- | | **Total Revenue** | $431,707 | $390,564 | | **Income from Operations** | $11,339 | $6,671 | | **Net Income (Loss)** | $5,410 | $(14,283) | | **Net Loss Attributable to Common Stockholders** | $(2,779) | $(21,005) | | **Diluted EPS** | $(0.04) | $(0.36) | | **Total Assets** | $2,969,555 | $2,690,473 (as of Dec 31, 2023) | | **Total Liabilities** | $1,892,230 | $1,877,114 (as of Dec 31, 2023) | | **Total Equity** | $1,077,325 | $813,359 (as of Dec 31, 2023) | | **Net Cash from Operating Activities** | $17,085 | $32,616 | [Notes to Condensed Consolidated Financial Statements](index=12&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) These notes detail RadNet's business, accounting policies, segment changes, business combinations, debt structure, and subsequent events, including a March 2024 stock offering, Digital Health segment formation, California acquisitions, and April 2024 debt refinancing - The company operates **375 outpatient diagnostic imaging centers** as of March 31, 2024[27](index=27&type=chunk) - In March 2024, RadNet completed a public offering of **5,232,500 common stock shares**, raising **$230.2 million** in gross proceeds[27](index=27&type=chunk) - In Q1 2024, RadNet revised its reportable segments, combining the eRad business with the AI segment to form a new **Digital Health segment**, with prior periods retrospectively adjusted[87](index=87&type=chunk) Acquisitions in Q1 2024 (Imaging Center Segment) | Entity Acquired | Date Acquired | Total Consideration (in thousands) | Goodwill (in thousands) | | :--- | :--- | :--- | :--- | | Grossman Imaging Center of CMH, LLC | 3/31/2024 | $10,500 | $9,016 | | Providence Health System - Southern California | 3/31/2024 | $7,096 | $6,453 | | Antelope Valley Outpatient Imaging | 2/1/2024 | $3,530 | $687 | | **Total** | | **$21,126** | **$16,156** | - Subsequent to quarter-end, on April 18, 2024, RadNet refinanced its debt, securing an **$875.0 million term loan** and a **$282.0 million revolving credit facility**, extending maturities and reducing interest rates[121](index=121&type=chunk) - RadNet has agreements to acquire **Houston Medical Imaging, LLC (7 centers)** and **U.S. Imaging, Inc. (8 centers)** in Texas, with closures anticipated in Q2 2024[119](index=119&type=chunk)[120](index=120&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=29&type=section&id=ITEM%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses Q1 2024 financial results, noting a **10.5% increase in total revenue to $431.7 million** driven by same-center growth and acquisitions, with improved Imaging Center profitability and Digital Health segment revenue growth, alongside enhanced liquidity from a stock offering and debt refinancing [Results of Operations](index=36&type=section&id=Results%20of%20Operations) Q1 2024 total revenue increased **10.5% to $431.7 million**, with Imaging Center segment revenue up **9.9% to $417.0 million** driven by volume and advanced imaging, Digital Health segment revenue up **32.3% to $14.7 million**, and consolidated net income improving to **$5.4 million** with Adjusted EBITDA reaching **$58.5 million** Imaging Center Segment Revenue (Q1 2024 vs Q1 2023) | Metric | Q1 2024 (in thousands) | Q1 2023 (in thousands) | % Change | | :--- | :--- | :--- | :--- | | **Total Revenue** | $417,046 | $379,487 | 9.9% | | Same Center Revenue | $376,655 | $348,240 | 8.2% | - Same-center revenue growth was driven by a **1.6% increase in procedure volume**, with advanced modality imaging procedures growing by **5.1%**[152](index=152&type=chunk) Digital Health Segment Performance (Q1 2024 vs Q1 2023) | Metric | Q1 2024 (in thousands) | Q1 2023 (in thousands) | % Change | | :--- | :--- | :--- | :--- | | **Revenue** | $14,661 | $11,078 | 32.3% | | **Loss from Operations** | $(3,015) | $(2,518) | 19.7% | Reconciliation of Net Income to Adjusted EBITDA | Metric | Q1 2024 (in thousands) | Q1 2023 (in thousands) | | :--- | :--- | :--- | | Net income attributable to RadNet, Inc. common stockholders | $(2,779) | $(21,005) | | Adjustments (Taxes, Interest, D&A, etc.) | $61,241 | $69,170 | | **Adjusted EBITDA - Total Company** | **$58,462** | **$48,165** | [Liquidity and Capital Resources](index=41&type=section&id=Liquidity%20and%20Capital%20Resources) RadNet's liquidity significantly strengthened in Q1 2024, with cash increasing to **$527.0 million** due to **$218.3 million** net proceeds from a March stock offering and an additional **$167.9 million** from an April debt refinancing, ensuring sufficient capital for the next twelve months Cash Flow Summary (Q1 2024 vs Q1 2023) | Cash Flow Activity (in thousands) | Q1 2024 | Q1 2023 | | :--- | :--- | :--- | | Cash from Operating Activities | $17,085 | $32,616 | | Cash used in Investing Activities | $(60,937) | $(65,556) | | Cash from (used in) Financing Activities | $228,298 | $(3,821) | - Cash from financing activities in Q1 2024 was primarily driven by **$218.3 million** in net proceeds from a public common stock offering[184](index=184&type=chunk) - As of March 31, 2024, RadNet had **$821.2 million** in total term loan debt and **$187.4 million** available under its Barclays revolving credit facility, plus **$50.0 million** under its Truist facility[185](index=185&type=chunk) - In April 2024, RadNet refinanced its Barclays credit facility, securing an **$875.0 million term loan** and a **$282.0 million revolver**, extending maturities, reducing interest rates, and adding approximately **$167.9 million** in cash[186](index=186&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=42&type=section&id=ITEM%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) RadNet faces market risks primarily from foreign currency fluctuations in the UK, Netherlands, Canada, and Hungary, and interest rate changes on variable-rate debt, partially mitigated by interest rate swaps, where a **1% SOFR increase** would raise annual interest expense by **$2.6 million** - RadNet is exposed to foreign exchange risk from operations in Pound Sterling, Euro, Canadian Dollar, and Hungarian Forint, where a hypothetical **1% decline** would increase annual operating expenses by approximately **$0.3 million**[187](index=187&type=chunk) - RadNet uses interest rate swaps on a notional amount of **$400 million** to mitigate interest rate risk on its variable-rate term loans[188](index=188&type=chunk)[189](index=189&type=chunk) - A hypothetical **1% increase in SOFR rates** would increase annual interest expense by **$1.2 million** on the unhedged Barclays term loan and **$1.4 million** on the Truist term loan[189](index=189&type=chunk)[190](index=190&type=chunk) [Controls and Procedures](index=43&type=section&id=ITEM%204.%20Controls%20and%20Procedures) Management, including the CEO and CFO, concluded that RadNet's disclosure controls and procedures were effective as of March 31, 2024, with no material changes to internal control over financial reporting during Q1 2024 - The Principal Executive Officer and Principal Financial Officer concluded that disclosure controls and procedures were **effective as of March 31, 2024**[191](index=191&type=chunk) - No material changes in internal control over financial reporting occurred during the quarter[192](index=192&type=chunk) [PART II – OTHER INFORMATION](index=44&type=section&id=PART%20II%20%E2%80%93%20OTHER%20INFORMATION) [Legal Proceedings](index=44&type=section&id=ITEM%201.%20Legal%20Proceedings) RadNet is involved in various ordinary course legal proceedings, but does not anticipate their outcomes will materially adversely impact its financial condition or results of operations - RadNet does not expect current legal proceedings to have a **material adverse impact** on its business, financial condition, or operations[195](index=195&type=chunk) [Risk Factors](index=44&type=page&id=ITEM%201A.%20Risk%20Factors) This section refers to the risk factors detailed in RadNet's Annual Report on Form 10-K for December 31, 2023, noting that those and other unknown or immaterial risks could adversely affect the business - For information on business risks and uncertainties, the report directs readers to the risk factors section of the **Annual Report on Form 10-K for the year ended December 31, 2023**[196](index=196&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=44&type=section&id=ITEM%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) On March 27, 2024, RadNet issued **95,019 common stock shares**, valued at **$4.6 million**, in a private placement to settle a contingent liability from the Heart & Lung Imaging Limited acquisition, exempt from Securities Act registration - On March 27, 2024, RadNet issued **95,019 common stock shares** valued at **$4.6 million** to settle a contingent liability from the Heart & Lung Imaging Limited acquisition[197](index=197&type=chunk) - The issuance was conducted as a **private placement**, exempt from registration under Section 4(a)(2) of the Securities Act[197](index=197&type=chunk) [Exhibits](index=44&type=section&id=ITEM%206.%20Exhibits) This section lists exhibits filed with the 10-Q report, including amendments to executive employment agreements, the Third Amended and Restated First Lien Credit and Guaranty Agreement, and CEO and CFO certifications required by the Sarbanes-Oxley Act - Key exhibits filed include the new **Third Amended and Restated First Lien Credit and Guaranty Agreement** dated April 18, 2024[201](index=201&type=chunk) - Certifications by the CEO and CFO pursuant to **Sections 302 and 906 of the Sarbanes-Oxley Act** are included as exhibits[201](index=201&type=chunk)

RadNet, Inc. (NASDAQ:RDNT) Q1 2024 Results Conference Call May 9, 2024 10:30 AM ET Company Participants Mark Stolper - Executive Vice President & Chief Financial Officer Dr. Howard Berger - Chairman, President & Chief Executive Officer Conference Call Participants Brian Trance - Jefferies John Ransom - Raymond James Andrew Mok - Barclays Yuan Zhi - B. Riley Securities Jim Sidoti - Sidoti & Company Operator Good morning, everyone, and welcome to the RadNet, Inc. First Quarter 2021 Financial Results Conferenc ...

Imaging Center Segment Performance - Adjusted EBITDA for the Imaging Center segment in 2023 was $245.1 million, a 17.2% increase compared to 2022[2] - Revenue for the Imaging Center segment in 2023 was $1,604 million, a 12.5% increase compared to 2022[2] - 2024 guidance for the Imaging Center segment projects Total Net Revenue between $1,650 - $1,700 million, representing a growth of 5.3% - 8.5%[6] - 2024 guidance for the Imaging Center segment projects Adjusted EBITDA between $250 - $260 million, representing a growth of 11.4% - 15.8%[6] - Imaging Center segment performance: Revenue grew 8.6% to $415.3 million, Adjusted EBITDA increased 11.0% to $68.3 million, and same-center procedural volume grew 5.5% in Q4 2023[45][49] Digital Health Segment Performance - 2024 guidance for the Digital Health segment projects Total Net Revenue between $60 - $70 million, representing a growth of 21.0% - 41.2%[8] - 2024 guidance for the Digital Health segment projects Adjusted EBITDA Before Non-Capitalized R&D for DeepHealth Cloud OS & Generative AI between $12 - $14 million, representing a growth of 51.4% - 76.6%[8] - The Digital Health segment has over 500 outside customers and combines informatics businesses with AI operations[9] - Formation of Digital Health reporting segment: Combining AI operations with software and informatics businesses, with 2023 pro forma results showing $49.6 million in Revenue and $7.9 million in Adjusted EBITDA[60][61] AI Segment Growth and Investments - Non-Capitalized R&D investment in DeepHealth Cloud OS and generative AI was $1.3 million in Q4 2023[1] - Pre-tax losses related to the AI reporting segment were $5.0 million in Q4 2023[1] - The company expects significant growth in 2024 from AI revenue, particularly from Enhanced Breast Cancer Detection (EBCD) implementation and lung and prostate AI licensing in Europe[10] - AI segment growth: AI revenue surged 278.4% to $5.1 million in Q4 2023 and is expected to increase over 65% in 2024, with AI Adjusted EBITDA projected to break even by end of 2024[45][48] - Digital health initiatives: Migration to cloud-based solutions, development of DeepHealth OS suite, and expansion of AI-enhanced screening programs for breast, lung, and prostate cancer[48] Financial Performance and Metrics - Net income for 2023 was $30.3 million, a decrease from $33.6 million in 2022 and $44.3 million in 2021[19] - Net cash provided by operating activities in 2023 was $220.9 million, up from $146.4 million in 2022[19] - Total service revenue for Q4 2023 was $420.4 million, compared to $383.9 million in Q4 2022[20] - Adjusted EBITDA for Q4 2023 was $65.8 million, an increase from $57.2 million in Q4 2022[21] - Adjusted EBITDA for the full year 2023 was $232.3 million, up from $192.5 million in 2022[21] - Non-cash employee stock-based compensation for 2023 was $26.8 million, compared to $23.8 million in 2022[21] - Depreciation and amortization expenses for 2023 were $128.4 million, up from $115.9 million in 2022[19] - Net cash used in investing activities for 2023 was $201.5 million, a decrease from $246.9 million in 2022[19] - Proceeds from issuance of stock in 2023 were $245.8 million, compared to $0 in 2022[19] - EBITDA losses from the AI segment for 2023 were $12.8 million, down from $16.6 million in 2022[21] - Total current assets decreased from $579.276 million in 2022 to $367.184 million in 2023[22] - Total property, plant, equipment, and right-of-use assets slightly decreased from $1.200433 billion in 2022 to $1.169485 billion in 2023[22] - Total liabilities increased from $1.877114 billion in 2022 to $1.942455 billion in 2023[22] - Adjusted net income attributable to RadNet, Inc. common stockholders increased from $6.383 million in 2022 to $13.742 million in 2023[27] - Adjusted diluted net income per share attributable to RadNet, Inc. common stockholders increased from $0.11 in 2022 to $0.20 in 2023[27] - Total service revenue increased to $1,616,630 in 2023, up 13% from $1,430,061 in 2022[65] - Net income attributable to RadNet, Inc. common stockholders decreased to $3,044 in 2023 from $10,650 in 2022[65] - Cash and cash equivalents at the end of the period rose significantly to $342,570 in 2023 from $127,834 in 2022[66] - Basic net income per share attributable to RadNet, Inc. common stockholders dropped to $0.05 in 2023 from $0.19 in 2022[65] - Weighted average shares outstanding (basic) increased to 63,580,059 in 2023 from 56,293,336 in 2022[65] - Cash paid for interest during the period rose to $64,695 in 2023 from $39,151 in 2022[66] - Cost of operations, excluding depreciation and amortization, increased to $1,395,239 in 2023 from $1,264,346 in 2022[65] - Depreciation and amortization expenses grew to $128,391 in 2023 from $115,877 in 2022[65] - Interest expense increased to $64,483 in 2023 from $50,841 in 2022[65] - Cash paid for income taxes during the period rose to $1,587 in 2023 from $587 in 2022[66] Volume Growth and Procedural Metrics - MRI procedures increased from 352,009 in Q4 2022 to 398,625 in Q4 2023[35] - Total procedures increased from 2.376995 million in Q4 2022 to 2.565720 million in Q4 2023[35] - Volume growth across modalities: MRI volume increased 13.2%, CT volume grew 11.3%, and PET/CT volume rose 18.5% in Q4 2023 compared to Q4 2022[53] Expansion and Strategic Initiatives - 2024 expansion plans: Approximately a dozen new facilities to be opened, including entry into the Houston market through acquisition of seven imaging centers[47] - 2023 capital expenditures: $153.0 million, including $18.6 million for New Jersey Imaging Network and $19.8 million for equipment previously leased[62][63] Payor Class Breakdown - Commercial insurance accounted for 58.0% of payor class breakdown in Q4 2023[31] Record Financial Performance - RadNet reported record revenue and Adjusted EBITDA for Q4 2023 and released 2024 financial guidance[43] - Record Revenue and Adjusted EBITDA in Q4 2023: Revenue increased 9.5% to $420.4 million, with Adjusted EBITDA growing 15.0% to $65.8 million compared to Q4 2022[45][50] - Full-year 2023 results: Total Revenue increased 13.0% to $1,617 million, with Adjusted EBITDA growing 20.7% to $232.3 million compared to 2022[58] Financial Leverage and Liquidity - 2023 financial leverage improvement: Net debt to Adjusted EBITDA fell below 2.0x, with $342 million cash balance and Days Sales Outstanding of 32.0 at year-end 2023[46]

Financial Data and Key Metrics Changes - For Q4 2023, RadNet reported revenue from its Imaging Center segment of $415.3 million, an increase of 8.6% from the previous year, and adjusted EBITDA of $68.3 million, up 11% [19][37] - For the full year 2023, total company revenue was $1.604 billion, a 13% increase from $1.430 billion in 2022, with adjusted EBITDA of $232.3 million, reflecting a 20.7% increase [45][47] - The adjusted EBITDA margin for the Imaging Center segment was 15.3%, an increase of 60 basis points from 2022 [44] Business Line Data and Key Metrics Changes - MRI volume increased by 13.2%, CT volume by 11.3%, and PET/CT volume by 18.5% in Q4 2023 compared to the same quarter last year [38] - Same-center procedural volume growth was 5.5% for Q4 2023, with MRI volume up 10.8%, CT volume up 8.2%, and PET/CT volume up 17.4% [39] - The AI segment revenue grew 278% in 2023, with expectations of over 65% growth in 2024 [27] Market Data and Key Metrics Changes - Demand for RadNet's services remains strong across core markets as outpatient imaging shifts from expensive hospital settings to cost-efficient ambulatory sites [4] - The Houston metropolitan area, with a population of approximately 7.3 million, represents a new market entry for RadNet, expected to enhance growth opportunities [23] Company Strategy and Development Direction - RadNet is focusing on expanding joint ventures and health system initiatives, with 24 system joint ventures representing over 35% of its centers [5] - The company is investing in de novo imaging centers and newer technologies, including AI solutions, to drive growth [9][10] - A new digital health reporting segment will combine eRAD and DeepHealth OS software businesses, projected to grow by 20% to 40% in 2024 [29][32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's position for long-term growth, citing strong liquidity and capital resources compared to competitors [58] - The company anticipates continued strength in volumes and expects to benefit from new facility openings in 2024 [21][22] - Management highlighted the importance of AI in future healthcare, emphasizing RadNet's accumulated data and operational scale as competitive advantages [59] Other Important Information - RadNet's cash balance at year-end 2023 was over $342 million, with a net leverage ratio under 2x adjusted EBITDA [20] - The company plans to implement enhanced breast cancer detection services and expand its lung cancer screening program in collaboration with partners in the UK [25][26] Q&A Session Summary Question: What are the expectations for volume growth in 2024? - Management noted strong volume growth and the positive impact of joint ventures on profitability, indicating a bullish outlook for continued strength in volumes [66] Question: What is the strategy for entering the Houston market? - Management highlighted the attractiveness of the Houston market due to its size and growth potential, expressing high expectations for success in this new core market [71] Question: How will new technology impact scan times and capacity? - Management discussed ongoing investments in technology to reduce scan times and improve operational efficiency, which will help address capacity issues [79] Question: What is the expected contribution of acquisitions and de novo centers to EBITDA in 2024? - Management indicated that the contribution from acquisitions and de novo centers would be relatively small, estimating around $10 million to $15 million of the projected EBITDA [92] Question: When will AI initiatives start generating meaningful revenue? - Management suggested that it may take another year to 1.5 years to accumulate sufficient data to demonstrate the value of AI solutions to payers, which could lead to reimbursement [96]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-33307 RadNet, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 1 ...

Financial Data and Key Metrics Changes - In Q3 2023, consolidated revenue reached $402 million, a 14.8% increase from $350 million in Q3 2022 [57] - Adjusted EBITDA for Q3 2023 was $57.9 million, up 26.5% from $45.8 million in Q3 2022 [57] - Net income for Q3 2023 was $17.5 million, compared to $668,000 in Q3 2022, with diluted net income per share increasing to $0.25 from $0.01 [32][57] Business Line Data and Key Metrics Changes - Imaging centers reported revenue of $399.1 million in Q3 2023, with adjusted EBITDA increasing 20.3% to $60.4 million [31][43] - Total procedures performed in Q3 2023 were 2,511,19, with MRI volume increasing 11.7%, CT volume increasing 10.9%, and PET-CT volume increasing 17.7% compared to Q3 2022 [34][84] Market Data and Key Metrics Changes - The company is experiencing heavy demand in local markets, leading to significant scheduling backlogs [17] - The AI division's revenue has more than tripled year-over-year, with a sequential growth of over 21% from Q2 2023 [18] Company Strategy and Development Direction - The company is committed to expanding its AI capabilities, with plans to implement generative AI tools in business processes by Q2 2024 [19][46] - A new joint venture with Cedars-Sinai Medical System aims to enhance outpatient radiology access and streamline patient care [21][47] - The company plans to open approximately a dozen new de novo facilities in 2024, contributing significantly to growth and profitability [69] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about 2024 growth initiatives, despite anticipated Medicare cuts of $7 million to $9 million [92][93] - The company is focused on maintaining strong relationships with payers to mitigate the impact of reimbursement cuts [93] - Management highlighted the importance of staffing and technology investments to address labor shortages and improve operational efficiency [103] Other Important Information - The company reported a net debt to adjusted EBITDA ratio of approximately two times, indicating strong liquidity and low leverage [25] - Cash capital expenditures for 2023 are projected to be between $115 million and $125 million, reflecting investments in new facilities [62] Q&A Session Summary Question: Can you provide insights on the AI rollout and early findings? - Management reported a 35% enrollment rate for the early breast cancer detection program on the East Coast, with expectations for further adoption [100][102] Question: How do you view the labor impact progressing throughout 2024? - Management indicated that investments in technology and salary increases are expected to help attract more candidates and improve staffing levels [103] Question: What is the expected contribution from new de novo centers? - New centers are anticipated to contribute $3 million to $5 million in revenue with EBITDA margins around 20% [126] Question: Can you elaborate on the joint venture with Cedars-Sinai? - The joint venture is structured as an asset swap, enhancing outpatient imaging capabilities and patient access [135][139]